Brofaromine for social phobia: A multicenter, placebo-controlled, double-blind study

Journal of Clinical Psychopharmacology

Volumn 17, Issue 4, 1997, Pages 255-260

  Lott, Michael ^a   Greist, John H ^b,c   Jefferson, James W ^b   Kobak, Kenneth A ^b   Katzelnick, David J ^b   Katz, Richard J ^a   Schaettle, Sarah C ^b  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Dean Foundation for Health Research and Education   (United States)

^c Dean Found Hlth   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROFAROMINE; MONOAMINE OXIDASE INHIBITOR; PLACEBO;

ADULT; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOCIAL PHOBIA; TINNITUS; TREMOR; VERTIGO; XEROSTOMIA;

ADULT; BENZAMIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITORS; PHOBIC DISORDERS; PSYCHIATRIC STATUS RATING SCALES;

EID: 0030800198     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199708000-00003     Document Type: Article

References (46)

1. Kessler RC, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen HU, Kendler DS. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the national comorbidity survey. Arch Gen Psychiatry 1994;51:8-19.
2. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, Del Bene D, Liebowitz MR. Functional impairment in social phobia. J Clin Psychiatry 1994;55:322-31.
3. Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992;49:282-8.
4. Weiller E, Bisserbe JC, Boyer P, Lepine JP, Lecrubier Y. Social phobia in general health care, an unrecognized under treated disabling disorder. Br J Psychiatry 1996;168:169-74.
5. Cox BJ, Direnfeld DM, Swinson RP, Norton GR. Suicidal ideation and suicide attempts in panic disorder and social phobia. Am J Psychiatry 1994;151:882-7.
6. Abbar M, Chignon JM, Picot MC, Caer Y, Schenk L, Castelnau D. Social phobia in suicide attempters. New Research Abstracts, American Psychiatric Association 146th Annual Meeting, San Francisco, CA. May 1993:148.
7. Jefferson JW. Social phobia: a pharmacologic treatment overview. J Clin Psychiatry 1995;56[suppl 5]:18-24.
8. Liebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF. Phenelzine vs atenolol in social phobia: a placebo-controlled comparison. Arch Gen Psychiatry 1992;49:290-300.
9. Liebowitz MR, Fyer AJ, Gorman JM, Campeas R, Levin A. Phenelzine in social phobia. J Clin Psychopharmacol 1986;6:93-8.
10. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ. Cognitive-behavioral and pharmacological treatments of social phobia. Arch Gen Psychiatry 1991;48:938-15.
11. Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-8.
12. Versiani M, Nardi AE. Bromazepam in social phobia: a placebo-controlled double-blind study. J Bras Psiquiatr (in press).
13. James I, Savage I. Beneficial effect of nadolol on anxiety-induced disturbances of performance in musicians: a comparison with diazepam and placebo. Am Heart J 1984;108:1150-5.
14. Neftel KA, Adler RH, Kappeli L, Rossi M, Dolder M, Kaser HE, Bruggesser HH, Vorkauf H. Stage fright in musicians: a model illustrating the effect of beta blockers. Psychosom Med 1982;44:461-9.
15. Gorman JM, Liebowitz MR, Fyer AJ, Campeas R, Klein DF. Treatment of social phobia with atenolol. J Clin Psychopharmacol 1985;5:298-301.
16. Brantigan CO, Brantigan TA, Joseph N. Effect of beta blockade and beta stimulation on stage fright. Am J Ed 1982;72:88-94.
17. Fallon IRH, Lloyd GG, Harpin RE. The treatment of social phobia: real-life rehearsal with nonprofessional therapists. J Nerv Ment Dis 1981;169:180-4.
18. Katzelnick DJ, Kobak KA, Greist MH, Jefferson JW, Mantle MN, Berlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-71.
19. van Vliet IM, den Boer JA, Westenberg HG. Psychopharmacological treatment of social phobia a double blind placebo controlled study with fluvoxamine. Psychopharmacology 1994;115:128-34.
20. Sternbach H. Fluoxetine treatment of social phobia [letter]. J Clin Psychopharmacol 1990;10:230.
21. Schneier FR, Chin SJ, Hollander E, Liebowitz MR. Fluoxetine in social phobia [letter]. J Clin Psychopharmacol 1992;12:62-3.
22. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia. J Clin Psychopharmacol 1992;12:293-5.
23. van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993;54:27-32.
24. Ringold AL. Paroxetine efficacy in social phobia [letter]. J Clin Psychopharmacol 1990;10:230.
25. Stein MB, Chartier MJ, Hazen AL, Kroft CDL, Chale RA, Cote D, Walker JR. Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 1996;16:218-22.
26. van Amerigen M, Mancini C, Wilson C. Buspirone augmentation of selective serotonin reuptake inhibitors (SSRIs) in social phobia. J Affect Disord 1996;39:115-21.
27. Kelsey JE. Venlafaxine in social phobia. Psychopharmacol Bull 1995;31:767-71.
28. Beaumont G. A large open multicentre trial of clomipramine (Anafranil) in the management of phobic disorders. J Int Med Res 1977;5:116-23.
29. Pecknold JC, McClure DJ, Appeltauer L, Allan T, Wrzesinski L. Does tryptophan potentiate clomipramine in the treatment of agoraphobic and social phobic patients? Br J Psychiatry 1982;140: 484-90.
30. Bieck PR, Antonin K-H, Schulz R. Clinical pharmacology of selective reversible MAO-A inhibitors. In: Moller H-J, Paykel ES, eds. Renaissance of monoamine oxidase inhibitors: the new selective and reversible generation. International Congress and Symposium Series No. 187. London: Royal Society of Medicine Services, 1992:15-9.
31. Bisserbe JC, Lepine JP, Group GRP. Moclobemide in social phobia a pilot open study. Clin Neuropharmacol 1994;17[suppl 1]:S88-S94.
32. Versiani M, Nardi AE, Mundim FD, Alves AB, Liebowitz MR, Amrien R. Pharmacotherapy of social phobia, a controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-60.
33. Schneier FR, Davies SO, Goetz D, Campeas R, Fallon BA, Liebowitz MR. A controlled trial of moclobemide in social phobia Paper presented at the 149th annual meeting, American Psychiatric Association, New York, NY May 4-9, 1996.
34. van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-9.
35. Fahlen T, Nilsson H, Borg K, Humble M, Pauli U. Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. Acta Psychiatr Scand 1995;92:351-8.
36. Liebowitz MR. Social phobia. In: Klein DF, ed. Anxiety (Modern problems of pharmacopsychiatry series, vol. 22). New York: Karger, 1987:141-73.
37. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, Hollander E, Papp L, Goetz D. Pharmacotherapy of social phobia an interim report of a placebo-controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988;49:242-57.
38. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-9.
39. Guy W. ECDEU assessment manual for psychopharmacology, rev. ed. Rockville, MD: National Institute of Mental Health, US Department of Health, Education, and Welfare. Publication No. ADM 76-338, 1976.
40. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-5.
41. Turner SM, McCanna M, Beidel DC. Validity of the Social Avoidance and Distress and Fear of Negative Evaluation Scales. Behav Res Ther 1987;25:113-5.
42. Sheehan DV. The anxiety disease. New York: Bantam Books, 1983.
43. Chouinard G, Saxena BM, Nair NPV, Kutcher SP, Bakish D, Bradwejn J, Kennedy SH, Sharma V, Remick RA, Kukha-Mohamad AS, Beauclair L, Snaith J, Souza JD. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. Clin Neuropharmacol 1993;16:S52-S54.
44. Volz HP, Faltus F, Magyar I, Moller HJ. Brofaromine in treatment-resistant depressed patients - a comparative trial versus tranylcypromine. J Affect Disord 1994;30:209-17.
45. Baker DG, Diamond BI, Gillette G, Hamner M, Katzelnick U, Keller T, Mellman TA, Pontius E, Rosenthal M, Tucker P, van der Kolk BA, Katz R. A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology 1995;122:386-9.
46. van Vliet IM, Westenberg HG, den Boer JA. MAO inhibitors in panic disorder: clinical effects of treatment with brofaromine. A double blind placebo controlled study. Psychopharmacology 1993;112:483-9.